Phase I/Ib Study of Nivolumab in Combination With Therasphere (Yttrium-90) in Patients With Advanced Hepatocellular Carcinoma
Latest Information Update: 15 Oct 2021
At a glance
- Drugs Nivolumab (Primary) ; Yttrium-90 (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 17 Sep 2021 Status changed from active, no longer recruiting to completed.
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 28 Jul 2020 Status changed from recruiting to active, no longer recruiting.